Cannabinoid type 1 receptor (CB1R) regulates glutamate release and plays a key role in neuroprotection and neuroinflammation. Since CB1R is implicated in HIV-associated neurocognitive disorders (HAND), it is important to determine how its expression changes with the neurotoxic human immunodeficiency virus type-1 (HIV-1) transactivator of transcription (Tat) protein. This study examined CB1R dynamics in an inducible HIV-1 Tat transgenic mouse model.
Methods:
Tat expression was induced in Tat(+) mice using doxycycline (DOX). Longitudinal positron emission tomography (PET) with the CB1R-selective radiotracer [11C]-OMAR was performed at baseline, 2 weeks, and 3 months post-induction in Tat(–) and Tat(+) groups to track CB1R alterations across brain regions. Western blot analyses were conducted postmortem in the prefrontal cortex, striatum, hippocampus, cortex, cerebellum, and brainstem.
Results:
In a longitudinal PET imaging study, we observed a significant upregulation of CB1R expression in the cortex and cerebellum after 2 weeks of DOX treatment in both Tat(–) and Tat(+) mice; however, this increase was not maintained at the 3-month timepoint. Western blot analysis revealed region-specific changes in CB1R levels for both genotypes with upregulation observed at 2 weeks post DOX treatment. Notably, a significant interaction between genotype × DOX in the hippocampus, cerebellum, and brainstem exhibited significant CB1R alteration by Tat expression, suggesting region-dependent regulatory mechanisms.
Conclusion:
DOX treatment and Tat expression appear to affect CB1R levels in a region-specific manner, underscoring the complexity of HAND. The differences between PET imaging and Western blot results suggest that [11C]-OMAR may lack the affinity and sensitivity to detect subtle CB1R changes at the 3-month timepoint. The low resolution of PET imaging may be another factor contributing to the detection limit. Lastly, these findings emphasize the importance of using multiple methodologies to capture nuanced molecular alterations in neuroinflammatory conditions.
HarrisonKM, SongR, ZhangX. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr2010;53(1):124–130; doi: 10.1097/QAI.0b013e3181b563e7
3.
HeatonRK, FranklinDR, EllisRJ, et al.; HNRC Group. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: Differences in rates, nature, and predictors. J Neurovirol2011;17(1):3–16; doi: 10.1007/s13365-010-0006-1
4.
VellaS, SchwartlanderB, SowSP, et al.The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS2012;26(10):1231–1241; doi: 10.1097/QAD.0b013e32835521a3
5.
Martinez-PicadoJ, DeeksSG. Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS2016;11(4):417–423; doi: 10.1097/COH.0000000000000287
6.
EllisR, LangfordD, MasliahE. HIV and antiretroviral therapy in the brain: Neuronal injury and repair. Nat Rev Neurosci2007;8(1):33–44; doi: 10.1038/nrn2040
7.
MasliahE, HeatonRK, MarcotteTD, et al.Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol1997;42(6):963–972; doi: 10.1002/ana.410420618
8.
El-HageN, RodriguezM, DeverSM, et al.HIV-1 and morphine regulation of autophagy in microglia: Limited interactions in the context of HIV-1 infection and opioid abuse. J Virol2015;89(2):1024–1035; doi: 10.1128/JVI.02022-14
9.
KingJE, EugeninEA, BucknerCM, et al.HIV tat and neurotoxicity. Microbes Infect2006;8(5):1347–1357; doi: 10.1016/j.micinf.2005.11.014
10.
PrendergastMA, RogersDT, MulhollandPJ, et al.Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitive-site on the N-methyl-D-aspartate receptor. Brain Res2002;954(2):300–307.
11.
FittingS, KnappPE, ZouS, et al.Interactive HIV-1 Tat and morphine-induced synaptodendritic injury is triggered through focal disruptions in Na(+) influx, mitochondrial instability, and Ca(2)(+) overload. J Neurosci2014;34(38):12850–12864; doi: 10.1523/JNEUROSCI.5351-13.2014
12.
LuHC, MackieK. Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging2021;6(6):607–615; doi: 10.1016/j.bpsc.2020.07.016
13.
VasincuA, RusuRN, AbabeiDC, et al.Endocannabinoid modulation in neurodegenerative diseases: In pursuit of certainty. Biology (Basel)2022;11(3):440; doi: 10.3390/biology11030440
14.
WuMM, ZhangX, AsherMJ, et al.Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder. Brain Res2019;1724:146467; doi: 10.1016/j.brainres.2019.146467
15.
Yadav-SamudralaBJ, FittingS. Mini-review: The therapeutic role of cannabinoids in neuroHIV. Neurosci Lett2021;750:135717; doi: 10.1016/j.neulet.2021.135717
16.
GlassM. The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry2001;25(4):743–765; doi: 10.1016/s0278-5846(01)00162-2
17.
Fernandez-MoncadaI, Eraso-PichotA, Dalla TorT, et al.An enquiry to the role of CB1 receptors in neurodegeneration. Neurobiol Dis2023;184:106235; doi: 10.1016/j.nbd.2023.106235
NavarreteM, DiezA, AraqueA. Astrocytes in endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci2014;369(1654):20130599; doi: 10.1098/rstb.2013.0599
20.
MarsicanoG, GoodenoughS, MonoryK, et al.CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science2003;302(5642):84–88; doi: 10.1126/science.1088208
21.
WalterL, StellaN. Cannabinoids and neuroinflammation. Br J Pharmacol2004;141(5):775–785; doi: 10.1038/sj.bjp.0705667
22.
GreenMV, RaybuckJD, ZhangX, et al.Scaling synapses in the presence of HIV. Neurochem Res2019;44(1):234–246; doi: 10.1007/s11064-018-2502-2
23.
ZhangW, XiaoD, MaoQ, et al.Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther2023;8(1):267; doi: 10.1038/s41392-023-01486-5
24.
MatsudaLA, BonnerTI, LolaitSJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol1993;327(4):535–550; doi: 10.1002/cne.903270406
25.
HowlettAC, BarthF, BonnerTI, et al.International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev2002;54(2):161–202; doi: 10.1124/pr.54.2.161
26.
NavarreteM, AraqueA. Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron2010;68(1):113–126; doi: 10.1016/j.neuron.2010.08.043
27.
Oliveira da CruzJF, RobinLM, DragoF, et al.Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse. Neuroscience2016;323:35–42; doi: 10.1016/j.neuroscience.2015.05.002
28.
Di MarzoV, MelckD, BisognoT, et al.Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci1998;21(12):521–528; doi: 10.1016/s0166-2236(98)01283-1
29.
JacobsIR, XuC, HermesDJ, et al.Inhibitory control deficits associated with upregulation of CB(1)R in the HIV-1 Tat transgenic mouse model of hand. J Neuroimmune Pharmacol2019;14(4):661–678; doi: 10.1007/s11481-019-09867-w
30.
BorganF, BeckK, ButlerE, et al.The effects of cannabinoid 1 receptor compounds on memory: A meta-analysis and systematic review across species. Psychopharmacology (Berl)2019;236(11):3257–3270; doi: 10.1007/s00213-019-05283-3
31.
WiseLE, ThorpeAJ, LichtmanAH. Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol. Neuropsychopharmacology2009;34(9):2072–2080; doi: 10.1038/npp.2009.31
32.
BenitoC, KimWK, ChavarriaI, et al.A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci2005;25(10):2530–2536; doi: 10.1523/Jneurosci.3923-04.2005
33.
Cosenza-NashatMA, BaumanA, ZhaoML, et al.Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities. Neuropathol Appl Neurobiol2011;37(5):464–483; doi: 10.1111/j.1365-2990.2011.01177.x
34.
RamirezSH, ReichenbachNL, FanS, et al.Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists. J Leukoc Biol2013;93(5):801–810; doi: 10.1189/jlb.1012523
35.
SloanME, GrantCW, GowinJL, et al.Endocannabinoid signaling in psychiatric disorders: A review of positron emission tomography studies. Acta Pharmacol Sin2019;40(3):342–350; doi: 10.1038/s41401-018-0081-z
36.
HortiAG, FanH, KuwabaraH, et al.11C-JHU75528: A radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med2006;47(10):1689–1696.
37.
HortiAG, Van LaereK. Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain. Curr Pharm Des2008;14(31):3363–3383; doi: 10.2174/138161208786549380
38.
KantonenT, KarjalainenT, PekkarinenL, et al.Cerebral mu-opioid and CB(1) receptor systems have distinct roles in human feeding behavior. Transl Psychiatry2021;11(1):442; doi: 10.1038/s41398-021-01559-5
39.
KantonenT, PekkarinenL, KarjalainenT, et al.Obesity risk is associated with altered cerebral glucose metabolism and decreased mu-opioid and CB(1) receptor availability. Int J Obes (Lond)2022;46(2):400–407; doi: 10.1038/s41366-021-00996-y
40.
BorganF, LaurikainenH, VeroneseM, et al.; METSY Group. In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis. JAMA Psychiatry2019;76(10):1074–1084; doi: 10.1001/jamapsychiatry.2019.1427
41.
DickensAM, BorganF, LaurikainenH, et al.Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. NPJ Schizophr2020;6(1):21; doi: 10.1038/s41537-020-00110-7
42.
AjalinRM, Al-AbdulrasulH, TuiskuJM, et al.Cannabinoid receptor type 1 in Parkinson’s disease: A positron emission tomography study with [(18) F]FMPEP-d(2). Mov Disord2022;37(8):1673–1682; doi: 10.1002/mds.29117
43.
CeccariniJ, CasteelsC, AhmadR, et al.Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson’s disease. Eur J Nucl Med Mol Imaging2019;46(11):2348–2357; doi: 10.1007/s00259-019-04445-x
44.
Van LaereK, CasteelsC, DhollanderI, et al.Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med2010;51(9):1413–1417; doi: 10.2967/jnumed.110.077156
45.
CeccariniJ, WeltensN, LyHG, et al.Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: A [(18)F]MK-9470 PET study. Transl Psychiatry2016;6(7):e853; doi: 10.1038/tp.2016.118
46.
CeccariniJ, De HertM, Van WinkelR, et al.Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage2013;79:304–312; doi: 10.1016/j.neuroimage.2013.04.052
47.
WongDF, KuwabaraH, HortiAG, et al.Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage2010;52(4):1505–1513; doi: 10.1016/j.neuroimage.2010.04.034
48.
HeranceR, RojasS, AbadS, et al.Positron emission tomographic imaging of the cannabinoid type 1 receptor system with [(1)(1)C]OMAR ([(1)(1)C]JHU75528): Improvements in image quantification using wild-type and knockout mice. Mol Imaging2011;10(6):481–487.
49.
XuC, HermesDJ, NwangumaB, et al.Endocannabinoids exert CB1 receptor-mediated neuroprotective effects in models of neuronal damage induced by HIV-1 Tat protein. Mol Cell Neurosci2017;83:92–102; doi: 10.1016/j.mcn.2017.07.003
50.
Yadav-SamudralaBJ, GormanBL, DodsonH, et al.Effects of acute Delta(9)-tetrahydrocannabinol on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice. Brain Res2024;1822:148638; doi: 10.1016/j.brainres.2023.148638
51.
AndersenAB, LawI, KrabbeKS, et al.Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation2010;7:13; doi: 10.1186/1742-2094-7-13
52.
HammoudDA, SinharayS, SteinbachS, et al.Global and regional brain hypometabolism on FDG-PET in treated HIV-infected individuals. Neurology2018;91(17):e1591–e1601; doi: 10.1212/WNL.0000000000006398
53.
TowgoodKJ, PitkanenM, KulasegaramR, et al.Regional cerebral blood flow and FDG uptake in asymptomatic HIV-1 men. Hum Brain Mapp2013;34(10):2484–2493; doi: 10.1002/hbm.22078
54.
HermesDJ, JacobsIR, KeyMC, et al.Escalating morphine dosing in HIV-1 Tat transgenic mice with sustained Tat exposure reveals an allostatic shift in neuroinflammatory regulation accompanied by increased neuroprotective non-endocannabinoid lipid signaling molecules and amino acids. J Neuroinflammation2020;17(1):345; doi: 10.1186/s12974-020-01971-6
55.
LeeDE, YueX, IbrahimWG, et al.Lack of neuroinflammation in the HIV-1 transgenic rat: An [(18)F]-DPA714 PET imaging study. J Neuroinflammation2015;12:171; doi: 10.1186/s12974-015-0390-9
56.
VennetiS, LoprestiBJ, WangG, et al.PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. J Clin Invest2004;113(7):981–989; doi: 10.1172/JCI20227
57.
VermaP, AsopaRV. Incidental global hypometabolism in the brain of patient with AIDS-related dementia seen on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Indian J Nucl Med2018;33(1):73–75; doi: 10.4103/ijnm.IJNM_108_17
58.
HammoudDA, EndresCJ, HammondE, et al.Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV. Neuroimage2010;49(3):2588–2595; doi: 10.1016/j.neuroimage.2009.10.037
59.
LeeDE, ReidWC, IbrahimWG, et al.Imaging dopaminergic dysfunction as a surrogate marker of neuropathology in a small-animal model of HIV. Mol Imaging2014;13; doi: 10.2310/7290.2014.00031
60.
SinharayS, LeeD, ShahS, et al.Cross-sectional and longitudinal small animal PET shows pre and post-synaptic striatal dopaminergic deficits in an animal model of HIV. Nucl Med Biol2017;55:27–33; doi: 10.1016/j.nucmedbio.2017.08.004
61.
CareyAN, SypekEI, SinghHD, et al.Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res2012;229(1):48–56; doi: 10.1016/j.bbr.2011.12.019
62.
Yadav-SamudralaBJ, DodsonH, RamineniS, et al.Cannabinoid receptor 1 positive allosteric modulator ZCZ011 shows differential effects on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice. PLoS One2024;19(6):e0305868; doi: 10.1371/journal.pone.0305868
63.
ZhaoX, FanY, VannPH, et al.Long-term HIV-1 Tat expression in the brain led to neurobehavioral, pathological, and epigenetic changes reminiscent of accelerated aging. Aging Dis2020;11(1):93–107; doi: 10.14336/AD.2019.0323
64.
Bruce-KellerAJ, Turchan-CholewoJ, SmartEJ, et al.Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia2008;56(13):1414–1427; doi: 10.1002/glia.20708
65.
ChauhanA, TurchanJ, PocernichC, et al.Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem2003;278(15):13512–13519; doi: 10.1074/jbc.M209381200
66.
FanH, RavertHT, HoltDP, et al.Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-[11 C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([11 C]JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-[11 C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([11 C]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor. J Label Compd Radiopharm2006;49:1021–1036.
67.
Yadav-SamudralaBJ, GormanBL, BarmadaKM, et al.Effects of acute cannabidiol on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice. Front Neurosci2024;18:1358555; doi: 10.3389/fnins.2024.1358555
68.
NormandinMD, ZhengMQ, LinKS, et al.Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: Assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. J Cereb Blood Flow Metab2015;35(8):1313–1322; doi: 10.1038/jcbfm.2015.46
69.
NassSR, HahnYK, McLaneVD, et al.Chronic HIV-1 Tat exposure alters anterior cingulate cortico-basal ganglia-thalamocortical synaptic circuitry, associated behavioral control, and immune regulation in male mice. Brain Behav Immun Health2020;5:100077; doi: 10.1016/j.bbih.2020.100077
70.
DasAT, TenenbaumL, BerkhoutB. Tet-on systems for doxycycline-inducible gene expression. Curr Gene Ther2016;16(3):156–167; doi: 10.2174/1566523216666160524144041
71.
WardRJ, PedianiJD, MilliganG. Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A. J Biol Chem2011;286(43):37414–37428; doi: 10.1074/jbc.M111.287649
72.
Jean-GillesL, BraitchM, LatifML, et al.Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells. Acta Physiol (Oxf)2015;214(1):63–74; doi: 10.1111/apha.12474
73.
BasavarajappaBS, SubbannaS. Molecular insights into epigenetics and cannabinoid receptors. Biomolecules2022;12(11):1560; doi: 10.3390/biom12111560
74.
LeeH, ParkJW, KimSP, et al.Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia. Neurobiol Dis2009;34(2):189–198; doi: 10.1016/j.nbd.2008.12.012
75.
YangYL, WangLX, FeiXM, et al.[The effect of doxycycline on the expression of MMP-2 and MMP-9 in multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi2022;30(2):487–492; doi: 10.19746/j.cnki.issn.1009-2137.2022.02.027
76.
EthellIM, EthellDW. Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets. J Neurosci Res2007;85(13):2813–2823; doi: 10.1002/jnr.21273
77.
MukhopadhyayS, TulisDA. Endocannabinoid regulation of matrix metalloproteinases: Implications in ischemic stroke. Cardiovasc Hematol Agents Med Chem2007;5(4):311–318; doi: 10.2174/187152507782109917
78.
OgutD, ReelB, Gonen KorkmazC, et al.Doxycycline down-regulates matrix metalloproteinase expression and inhibits NF-κB signaling in LPS-induced PC3 cells. Folia Histochem Cytobiol2016;54(4):171–180; doi: 10.5603/FHC.a2016.0022
79.
GinsburgBC, HenslerJG. Age-related changes in CB1 receptor expression and function and the behavioral effects of cannabinoid receptor ligands. Pharmacol Biochem Behav2022;213:173339; doi: 10.1016/j.pbb.2022.173339
80.
MinerbiA, HäuserW, FitzcharlesMA. Medical cannabis for older patients. Drugs Aging2019;36(1):39–51; doi: 10.1007/s40266-018-0616-5
81.
SwintonMK, SundermannEE, PedersenL, et al.Alterations in brain cannabinoid receptor levels are associated with HIV-associated neurocognitive disorders in the ART era: Implications for therapeutic strategies targeting the endocannabinoid system. Viruses2021;13(9):1742; doi: 10.3390/v13091742
82.
XingG, CarltonJ, JiangX, et al.Differential expression of brain cannabinoid receptors between repeatedly stressed males and females may play a role in age and gender-related difference in traumatic brain injury: Implications from animal studies. Front Neurol2014;5:161; doi: 10.3389/fneur.2014.00161
83.
XingG, CarltonJ, ZhangL, et al.Cannabinoid receptor expression and phosphorylation are differentially regulated between male and female cerebellum and brain stem after repeated stress: Implication for PTSD and drug abuse. Neurosci Lett2011;502(1):5–9; doi: 10.1016/j.neulet.2011.05.013
84.
CraftRM, MarusichJA, WileyJL. Sex differences in cannabinoid pharmacology: A reflection of differences in the endocannabinoid system? Life Sci2013;92(8–9):476–481; doi: 10.1016/j.lfs.2012.06.009
85.
RomeroJ, Garcia-PalomeroE, BerrenderoF, et al.Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse1997;26(3):317–323; doi: 10.1002/(SICI)1098-2396(199707)26:3<317::AID-SYN12>3.0.CO;2-S
86.
LopezHH. Cannabinoid-hormone interactions in the regulation of motivational processes. Horm Behav2010;58(1):100–110; doi: 10.1016/j.yhbeh.2009.10.005
87.
Rodriguez de FonsecaF, CebeiraM, RamosJA, et al.Cannabinoid receptors in rat brain areas: Sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci1994;54(3):159–170; doi: 10.1016/0024-3205(94)00585-0
88.
GonzalezS, BisognoT, WengerT, et al.Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun2000;270(1):260–266; doi: 10.1006/bbrc.2000.2406
89.
WuMM, ThayerSA. HIV Tat protein selectively impairs CB1 receptor-mediated presynaptic inhibition at excitatory but not inhibitory synapses. eNeuro2020;7(3).
90.
Santa-CeciliaFV, LeiteCA, Del-BelE, et al.The neuroprotective effect of doxycycline on neurodegenerative diseases. Neurotox Res2019;35(4):981–986; doi: 10.1007/s12640-019-00015-z
91.
LancelotS, ZimmerL. Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci2010;31(9):411–417; doi: 10.1016/j.tips.2010.06.002
92.
YaoR, LecomteR, CrawfordES. Small-animal PET: What is it, and why do we need it? J Nucl Med Technol2012;40(3):157–165; doi: 10.2967/jnmt.111.098632
93.
HouL, RongJ, HaiderA, et al.Positron emission tomography imaging of the endocannabinoid system: Opportunities and challenges in radiotracer development. J Med Chem2021;64(1):123–149; doi: 10.1021/acs.jmedchem.0c01459
94.
AlfarHR, PariserDN, ChanzuH, et al.Protocol for optimizing production and quality control of infective EcoHIV virions. STAR Protoc2023;4(3):102368; doi: 10.1016/j.xpro.2023.102368
95.
GuCJ, BorjabadA, HadasE, et al.EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. PLoS Pathog2018;14(6):e1007061; doi: 10.1371/journal.ppat.1007061
96.
HoneycuttJB, LiaoB, NixonCC, et al.T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest2018;128(7):2862–2876; doi: 10.1172/JCI98968
97.
HoneycuttJB, WahlA, FilesJK, et al.In situ analysis of neuronal injury and neuroinflammation during HIV-1 infection. Retrovirology2024;21(1):11; doi: 10.1186/s12977-024-00644-z
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
